Whitepaper: Upstream process intensification
Posted: 5 February 2021 | Merck | No comments yet
Strategies for upstream process intensification can be leveraged for cell line development, the seed train, production and cell culture media formulation.
The Facility of the Future represents a transformation in how biologics are developed and manufactured. Upstream intensification is one strategy that will enable this revolution by significantly driving down costs through an increase in volumetric productivity.
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Lab Automation, Manufacturing